Prospective study evaluates neurological outcomes and imaging metrics in AQP4-Ab+ neuromyelitis optica after ravulizumab treatment, suggesting new insights into disease management.
To prospectively study ravulizumab treatment outcomes, enhance knowledge on conventional MRI outcomes, assess for occult disease activity via quantitative imaging metrics, identify serum biomarkers related to disease progression, and explore contemporary social factors that may impact neurological outcomes in people with AQP4-Ab positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD).
No takes yet. Share an insight, caveat, or question.
Okuda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: